Nanosensors based on LSPR are able to serologically differentiate dengue from Zika infections
nanosignals
NanoSignals develops assays based on localized surface plasmon resonance (LSPR) using gold nanorods. The tests detect molecules, such as specific antibodies and antigens, and are read on microplate spectrophotometers.
Technology
The same nanoplatform can be built with different capture molecules. Changing the molecule changes the test's target; preparation and reading stay the same. In published studies, the platform distinguished dengue infection from Zika infection and detected antibodies against SARS-CoV-2 with much higher sensitivity than traditional tests such as ELISA.
Brazilian technology born from research at the Federal University of Minas Gerais (UFMG). The platform's patents belong to UFMG and are licensed to NanoSignals, which leads product development through to its final, market-ready form.
Publications
The platform's results are published in high-impact international scientific journals.
Nanosensors based on LSPR are able to serologically differentiate dengue from Zika infections
Serologic LSPR-nanosensor against SARS-CoV-2 antibodies and related variants outperforms ELISA in sensitivity
We work with clinical laboratories, research centers and companies interested in validating, licensing or developing products that harness the potential of our platform.
